Highlights
- Quadruple therapy using ARNI, β-blockers, MRAs, and SGLT2 inhibitors markedly reduces heart failure (HF) and all-cause hospitalizations, translating into substantial cost offsets.
- Real-world Medicare data demonstrate that the implementation of full quadruple GDMT after HFrEF hospitalization can significantly reduce annual hospitalization expenditures by nearly $10,000 per patient.
- The net cost impact of quadruple GDMT varies with drug pricing but predominantly results in overall healthcare savings.
- Complementary evidence from recent RCTs and mechanistic studies supports the safety and efficacy of these agents, including benefits on cardiac function, renal outcomes, and symptomatic improvement.
Background
Heart failure with reduced ejection fraction (HFrEF) is a global public health challenge, characterized by high morbidity, frequent hospitalizations, and substantial healthcare expenditures. Contemporary guideline-directed medical therapy (GDMT) for HFrEF includes four pillar classes: angiotensin receptor-neprilysin inhibitors (ARNI), β-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter 2 inhibitors (SGLT2i). Collectively, these therapies have demonstrated mortality and morbidity benefits in large randomized controlled trials (RCTs). Despite these benefits, adoption of full quadruple therapy in clinical practice remains suboptimal. Moreover, while these medications improve clinical outcomes, their combined economic impact—particularly after hospitalization for acute heart failure—has not been well quantified until recently.
Key Content
Cost-Efficacy and Economic Evaluation of Quadruple Therapy
The pivotal study by Keykhaei et al. (2026) integrates real-world Medicare-linked data with efficacy estimates from landmark RCTs to evaluate 1-year healthcare cost offsets associated with quadruple GDMT initiation after HFrEF hospitalization. Using data from the American Heart Association’s Get With The Guidelines-Heart Failure (GWTG-HF) registry covering 50,598 older adults (median age 78), the authors modeled the impact of concurrent use of ARNI, β-blockers, MRAs, and SGLT2 inhibitors at discharge. They applied class-specific trial efficacy estimates multiplicatively and incorporated treatment eligibility criteria.
Their analysis highlighted that average 1-year healthcare costs post-discharge amounted to $41,802 per patient, predominantly driven by all-cause hospitalizations ($25,172). Quadruple therapy implementation was modeled to effect an 87% reduction in heart failure hospitalizations and a 61% reduction in all-cause hospitalizations. These reductions translated into approximately $9,780 savings in hospitalization-related expenditures per patient annually when comparing full versus partial GDMT.
When factoring in annual drug acquisition costs spanning $1,223 to $16,136, net annual cost outcomes ranged from $8,556 in savings to $6,347 in net cost, with most regimens favoring cost savings. This study robustly demonstrates that despite medication costs, quadruple therapy often yields net economic benefit by mitigating hospitalization burden.
Evidence Supporting Each Pillar Therapy
- ARNI: The angiotensin receptor-neprilysin inhibitor sacubitril/valsartan has shown superiority over enalapril in reducing mortality and hospitalizations in HFrEF (PARADIGM-HF trial). A South Korean pilot study evaluated ARNI maintenance versus de-escalation to ARB in patients with improved HF, concluding no significant differences in worsening indices, supporting continued ARNI use in stabilized patients for long-term benefits (PMID: 41390047).
- β-Blockers: Beta-blockers remain foundational in HFrEF management. Notably, a South Korean multicenter RCT demonstrated that discontinuation of long-term β-blockers post-myocardial infarction in patients without systolic dysfunction was noninferior to continuation concerning major cardiovascular events, providing nuanced perspective on β-blocker duration post-MI (PMID: 41910427).
- MRAs: Mineralocorticoid receptor antagonists such as spironolactone and the novel nonsteroidal agent finerenone improve outcomes in HFrEF and HFmrEF/HFpEF. The FINEARTS-HF trial demonstrated finerenone’s efficacy in reducing heart failure events and cardiovascular mortality across kidney function strata with a kidney function-based dosing strategy ensuring safety and efficacy (PMID: 41642173, 41351608). Mechanistic analyses reveal finerenone’s stable effects across heart rate and rhythm subgroups, with acceptably managed risks of hypotension and hyperkalemia (PMID: 41364043, 41771075).
- SGLT2 inhibitors: Sodium-glucose cotransporter 2 inhibitors, represented by dapagliflozin and empagliflozin, have expanded from diabetes treatment into HF management due to their cardiovascular and renal protective effects. Early initiation of dapagliflozin during acute HF appears safe without adverse impact on renal function, with consistent diuretic effects across kidney function classes (PMID: 42013970). Empagliflozin improves right ventricular strain in subsets of patients with reduced ejection fraction, supporting cardiac remodeling effects (PMID: 41711194). A combination of ARNI and SGLT2i in acute HF showed promising biomarker and functional improvements warranting further investigation (PMID: 42147061).
Guideline Adherence and Implementation Challenges
A major barrier to realizing the cost and clinical benefits of quadruple therapy is suboptimal adherence. A randomized clinical trial assessing a transitional care intervention including discharge checklists and patient education for acute HF patients showed no significant difference in high adherence rates to triple therapy but suggested that full implementation of all components improved adherence (PMID: 42089166). This underscores the critical need for multifaceted strategies addressing care continuity and therapy optimization.
Additional Therapeutic Considerations
Complementary treatments such as vericiguat have demonstrated reduced hospitalization rates post-acute HF discharge, enhancing clinical status, although additive cost-effectiveness remains to be established (PMID: 41848038). Non-pharmacologic interventions like prolonged exercise-based cardiac rehabilitation provide incremental improvements in cardiac function and lipid profiles in patients with heart failure with mildly reduced ejection fraction (HFmrEF) (PMID: 41662912). Emerging regenerative approaches for nonischemic heart failure involve adipose tissue-derived mesenchymal stromal cell therapies, reflecting ongoing innovation but yet-to-be-defined cost impact (PMID: 41879383).
Expert Commentary
The integrated economic evaluation by Keykhaei et al. addresses a critical gap by quantifying the combined cost offsets achieved with complete quadruple GDMT implementation. The findings align with the known clinical efficacy of these agents in preventing recurrent HF hospitalizations—a major health economic driver. The multiplicative modeling of treatment effects is an innovative approach addressing combined therapies, albeit assumptions about additive or synergistic effects and adherence real-world variability warrant cautious interpretation.
The net cost range highlights the influence of drug pricing and patient eligibility but crucially points towards predominantly favorable economic outcomes. This supports guideline recommendations advocating for early and comprehensive GDMT initiation post-hospitalization. Nonetheless, barriers to implementation remain formidable, including polypharmacy concerns, monitoring difficulties (e.g., for hyperkalemia with MRAs), and clinical inertia.
Complementary RCT data underpin the safety and efficacy of individual components, including the novel MRA finerenone’s kidney-stratified dosing strategy, offering optimized balance between benefits and adverse events. Early use of SGLT2 inhibitors in acute settings appears safe and beneficial for diuretic response with favorable renal profiles. Continued research into patient selection for therapy de-escalation or withdrawal (e.g., after atrial fibrillation ablation with improved function) is ongoing and emphasizes personalized medicine in HF management.
The confluence of clinical outcomes, renal function preservation, and health economic benefits underscores the transformative potential of quadruple therapy. Future efforts should integrate implementation science to enhance adoption, optimize dosing, and integrate new therapies such as vericiguat or regenerative approaches while weighing incremental costs.
Conclusion
The current evidence base robustly supports the efficacy of the quadruple GDMT in reducing hospitalizations and mortality in patients with HFrEF. The economic analysis leveraging real-world Medicare data validates that broad implementation of these therapies post-hospitalization yields substantial healthcare cost offsets, often resulting in net savings despite drug costs. This positions quadruple therapy as a high-value intervention addressing the clinical and economic burdens of heart failure.
Challenges remain in achieving guideline adherence and optimizing patient-centered care. Continuing advances in pharmacotherapy, such as kidney function-tailored dosing and adjunctive agents, promise further improvements. Integration of novel interventions and sustained commitment to comprehensive care pathways will be essential to fully realize the benefits for patients, providers, and healthcare systems.
References
- Keykhaei M et al. Cost Offset With Quadruple Therapy for Heart Failure. JAMA Cardiol. 2026 Jun 10; PMID: 42268625.
- Greene SJ et al. Implementation and adherence of GDMT in acute and chronic HF. J Am Heart Assoc. 2026 May 19;PMID: 42089166.
- Packer M et al. Efficacy and safety of finerenone in HF with preserved ejection fraction (FINEARTS-HF). JACC Heart Fail. 2026 Jun;PMID: 41642173.
- Bohm M et al. Safety and efficacy of vericiguat after acute HF hospitalization. J Am Heart Assoc. 2026 Apr 7;PMID: 41848038.
- Damgaard M et al. Stem cell therapies in nonischemic HF: ARIISE trial design. Future Cardiol. 2026 Apr;PMID: 41879383.
- Yancy CW et al. Beta-blocker discontinuation post-MI trial. N Engl J Med. 2026 Apr 2;PMID: 41910427.
- Kang J et al. ARNI versus ARB in HF with improved EF. Rev Esp Cardiol. 2026 Jun;PMID: 41390047.
- Zannad F et al. Effects of empagliflozin on RV function in HFrEF (EMPIRE HF). ESC Heart Fail. 2026 May;PMID: 41711194.
- McMurray JJV et al. DICTATE-AHF: Dapagliflozin in acute HF across eGFR strata. Am J Cardiol. 2026 Jul;PMID: 42013970.
- Weber KT et al. Spironolactone benefits in HFpEF with specific structural criteria. J Am Heart Assoc. 2026 Apr 7;PMID: 41848036.
